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ABSTRACT
Benzothiazole-piperazine derivatives prepared previously, 1h 
and 1j are potential anticancer agents. Since the mutagenic 
and genotoxic properties of anticancer drugs compose an 
essential issue to be researched, this study is focused on 
the analysis of the mutagenicity and genotoxicity of these 
molecules. The mutagenicity of 1h and 1j were determined by 
Ames test performed on Salmonella TA98 and TA100 strains. 
Sample 1j was mutagenic on TA98 bacterial strain. However, 
compound 1h was not mutagenic in bacterial strains TA98 
and TA100 with and without S9 activation. The genotoxicity 
of 1h was evaluated by the chromosomal aberration assay on 
human lymphocytes. Compound 1h was also not genotoxic 
in human lymphocytes in vitro. All results revealed that, 
1h was not mutagenic in the two Salmonella strains tested 
and was not genotoxic in chromosomal aberration assay. 
Therefore, results demonstrate that the described molecule 
is promising as a new anticancer drug without mutagenicity. 
Also, after performing Ames test with other recommended 
bacterial strains and in vivo experiments can be used safely 
for the development of new structures exhibiting anticancer 
activities.
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INTRODUCTION
Cancer as a very common health problem is a disease of 
cellular mutation, proliferation and abnormal cell growth 
(1). Anticancer drug development aims the generation of 
chemical structures that can control the growth of cancerous 
cells efficiently.
The aim of targeting cell proliferation is to arrest the cell 
cycle or cause cancer cell death using cytotoxic compounds. 
DNA is one of the main targets of these therapies because 
DNA replication is an essential phase of the cell cycle (2). 
Many of the cytotoxic agents commonly used to treat cancer 
patients cause high levels of DNA damage which initiate 
cell cycle checkpoints, leading to cell cycle arrest and/or cell 
death (3). As designed for inducing considerable damage to 
genetic material in cancer cells, anticancer drugs have to be 
studied for their genotoxic effects on normal cells in order 
to estimate their relative potencies to promote the growth of 
secondary malignancies (4).
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Drugs used in cancer chemotherapy have serious side effects, 
selectivity problems and potential to develop tolerance. 
Thus, discovering new anticancer drugs is crucial under 
these circumstances.
Benzothiazole derivatives have been extensively studied 
as potential anticancer drug candidates (5-10) and several 
attempts were made to modify the benzothiazole nucleus 
improving their antitumor activities. Modifications on the 
benzothiazole core have resulted in a more complex structure 
to develop a relationship between their structures and the 
antineoplastic activity (11).
In the previous studies of Gürdal et al., synthesis, 
characterization and anticancer activities of several 
benzothiazole-piperazine derivatives were presented. 
Among these compounds, aroyl substituted 1h and 1j 
were found to be active against HUH-7 (hepatocellular), 
MCF-7 (breast) and HCT-116 (colorectal) cancer cell lines. 
Although their direct mechanism of action has not been 
clarified yet, it was shown that these compounds cause 
apoptosis by cell cycle arrest at subG1 phase by Hoechst 
staining and Fluorescence Activated Cell Sorting (FACS) 
assays (12). Many studies focused on the evaluation of the 
genotoxicity of widely used anticancer agents in Turkey 
and around the world. For example; cisplatin (13-15), 
poly polymerases (16) and paclitaxel (17, 18) genotoxicity 
potential on somatic and/or germ cells were studied 
previously.
In this study, we aimed to determine the mutagenic and 
genotoxic properties of 1h and 1j using the Salmonella/
microsome assay on TA98 and TA100 strains and human 
lymphocytes in vitro since optimization studies of these 
compounds led to the discovery of a new family of 
benzothiazole compounds with promising anticancer 
properties.
MATERIALS AND METHODS
Chemicals
Sodium azide (SA), 4-nitro-o-phenylenediamine (NPD), 
biotin, histidine, nicotinamide adenine dinucleotide 
phosphate, glucose-6-phosphate, ampicillin trihydrate, 
mitomycin C (MMC), colchicine and agar were supplied 
from Sigma Aldrich Chemical Company (St Louis, Missouri, 
USA). Dimethyl sulfoxide (DMSO) was purchased from 
Acros (New Jersey, USA). 2-Aminofluorene (2-AF) was from 
Merck (Hohenbrunn, Germany) and nutrient broth was 
supplied from Hi Media laboratories Ltd (Mumbai, India). 
Peripheral blood karyotyping medium was purchased from 
the Gibco (Life Technologies, USA).
Synthesis of 1h and 1j
Compounds 1h and 1j were synthesized according to the 
procedure described by Gürdal et al. (12) (Figure 1).
S
N
H
NH3C
O
N
N
R
Compounds R 
Cancer Cell Line (GI50, µM) 
HCT-116 R2 MCF-7 R2 HUH-7 R2 
1h Benzoyl 0.9 1.0 9.2 1.0 0.7 0.9 
1j 2-Furoyl 1.3 0.7 4.3 0.8 4.5 0.9 
5-Fluorouracil 30.66  3.51  18.67  
 
Figure 1. Structures and cytotoxic activities of compounds 1h and 1j (12).
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Bacterial strains
Mutagenic activity was tested by the Salmonella/microsome 
assay, using the Salmonella typhimurium tester strains TA98 
and TA100 provided with and without metabolization activity. 
TA98 detects frameshift mutagens and TA100 detects base 
pair mutagens. These strains were primarily recommended 
by Maron and Ames (19) for routine mutagenicity assays. 
This test is an important tool for screening substances for 
potential carcinogenicity. The TA98 strain was provided by 
the Toxicology Department of the Faculty of Pharmacy of 
Gazi University (Ankara, Turkey) and the TA100 strain was 
received from the Marmara Research Center of the Turkish 
Scientific and Technological Research Council (Gebze, 
Turkey).
Genetic analysis of Salmonella typhimurium strains for 
Ames test
Salmonella typhimurium strains were checked before the 
experiment. The following steps were performed for a 
complete strain check (20, 21).
Histidine dependence
Bacteria from overnight culture grown in nutrient broth 
were plated on minimal glucose agar plates and histidine/
biotin plaques. Plates were left to incubate overnight at 37°C 
(Binder, USA). Growing was observed in histidine/biotin 
plaques but no growth was observed in minimal glucose agar 
plates, indicating that both Salmonella strains were histidine 
dependent.
Rfa marker
The presence of the Rfa marker was defined by the crystal 
violet sensitivity test. For this, 0.1 mL of bacterial culture 
was placed in 2 mL of top agar and kept at 45°C. Then, the 
bacterial-top agar mixture spread over nutrient agar. After 
solidification of the agar, a sterile filter paper disk was placed 
in the center of the plate and 10 µL of a sterile 0.1% crystal 
violet solution was applied on filter paper disk. Plates were 
incubated for 12 hours at 37°C. Both Salmonella strains 
showed a zone of growth inhibition surrounding the disk.
UVrB deletion
This mutation was identified by a sensitivity test to ultraviolet 
rays. Cultured bacteria were plated on nutrient agar. Two petri 
dishes were prepared with the same cultured bacteria. These 
plates were irradiated in a 15 W power with a UV lamp at a 
distance of 33 cm for 8 sec. Then, the plates were incubated 
for 24 hours at 37°C. Bacterial growth was not observed in 
the plate which was exposed to UVB. However, bacteria that 
were not exposed to UVB light showed proliferation.
R Factor Presence
A loopful of the plasmid carrying Salmonella culture was 
streaked across a minimal glucose agar plate supplemented 
with histidine/biotin and 24 mg/mL ampicillin. The plates 
were kept at 37°C for 24 hours. Growth was observed with 
tested strains TA98 and TA100.
Preparation of S9 Fraction
The rat liver homogenate was prepared according to 
methods of Ames et al. (22), Garner et al. (23) and Halder 
et al. (24). Two Sprague–Dawley male rats weighing 150–
200 g were provided from the Yeditepe University Medical 
School Experimental Research Center (YUDETAM) and 
the experimental protocol was approved by the ethical 
committee of Yeditepe University. Animals were fed with 
0.1% phenobarbital in their drinking water for 7 days. On 
day 6, no food was provided to rats. The following day, 
the animals were sacrificed and the rat liver homogenate 
(S9) was prepared by centrifugation at 9000g following the 
method of Maron and Ames (19). Approximately 2 mL of S9 
fractions were distributed in different small sterile cryo vials 
and quickly frozen and stored at -80°C.
Mutagenicity assays
Standard mutagenicity assays in plate incorporation tests 
were carried out by following the method of Maron and Ames 
procedure (19). Compounds 1h and 1j were dissolved in 
DMSO and different concentrations (0, 1, 10, 100, 1000 and 
5000 µg/plate) in 50 mL of DMSO were used for mutagenicity 
assay. Plates were co-incubated with the bacterial strains 
and the different concentrations of samples, inverted and 
placed at 37°C for 48 h in dark and revertant colonies were 
counted after incubation. To evaluate the impact of 1h and 
1j metabolites, similar experiments were also carried out by 
incubating bacteria and chemicals with liver S9. Four plates 
were used for each concentration tested with and without S9 
experiments.
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Five different concentrations of the test materials were used 
with 10 fold intervals between test points and the maximum 
test concentration was 5000 µg/plate as recommended by the 
Organization for Economic Cooperation and Development’s 
(OECD) guideline (25).
In vitro chromosomal aberration assay in human 
lymphocyte culture
For chromosomal aberration (CA) analysis, human blood 
samples were obtained from one male and one female healthy 
volunteers (aged between 25 and 35 years, non-smoker, non-
alcoholic, not under drug therapy and with no recent history 
of exposure to mutagens). Blood samples were collected in 
the heparinized vials, and 0.5 mL of blood was added to 5 
mL of Karyomax medium and incubated at 37°C. After 24 
h, three different concentrations of 1h (1.5, 3 and 6 µg /
mL of culture) were added to the blood culture. The stock 
solution was prepared by dissolving 1h in DMSO first, this 
solution is subsequently diluted with Karymax medium to be 
added to the culture media in the concentrations mentioned 
above. Two cultures were treated with each concentration 
of chemical (one from male and one from female blood 
samples) as recommended by the OECD guideline (26). 
Two sets of cultures were also treated with only DMSO and 
MMC (0.50 mg/mL) and were used as negative and positive 
controls. After 70 h of the blood culture, colchicine was 
added to the culture media to arrest the metaphase cells. 
At 72 h, cultures were harvested and slides were prepared 
for metaphase chromosomes following the method of De 
Chaudhuri et al. (27) and also OECD test guideline (26). 
All slides were coded, and 100 well-spread metaphase cells 
(46±2 chromosomes) per culture were scored for CA. A total 
of 200 metaphase cells were scored for each concentration 
of chemical and for both negative and positive controls. 
For the mitotic index (MI) analysis, 1000 cells/culture were 
scored, and the MI was expressed in percentages. CA was 
scored according to the World Health Organization (28) 
and OECD guideline (26). Frequency of aberrations per cell 
for chromatid type and chromosome types were calculated. 
Gaps were recorded as indicated in the OECD guideline but 
were not included neither as percentage of aberrant cells nor 
as frequency of aberrations per cell.
Statistical analysis
The differences between the groups were compared using 
SPSS 20 program. Experimental results were expressed as 
mean ± deviation. Dunnett’s multiple comparison test was 
carried out for mutagenicity CA analysis (29). The values of 
p < 0.05 was considered statistically significant.
RESULTS
The results of the mutagenicity assays induced by 1h and 1j 
in the TA98 and TA100 Salmonella strains with and without 
metabolic activation was given in Table 1. As expected, the 
positive control showed very high frequencies of revertant 
colonies when compared to the negative control.
Neither TA98 nor TA100 strains treated with 1h 
concentrations of 1–5000 µg/plate exhibited significant 
increase in revertant colonies number when compared with 
the negative control, suggesting no mutagenicity to the tested 
strains. For TA100 strain, toxicity was observed to appear 
for a 1h concentration of 1000 µg/plate of culture with and 
without S9 activation. For TA100, 5000 µg/plate was found 
to be a totally toxic concentration. In TA98 strain 1h did not 
influence indicator bacteria viability, suggesting no toxicity 
in the tested strain at concentrations up to ≤ 5000 µg/plate 
with or without S9 metabolic system. On the other hand, 1j 
increased the revertant colonies significantly when compared 
to negative control (p<0.05) indicating the mutagenic effect 
on TA98 strain with or without S9 activation. In the TA100 
strain treated with 1j concentrations of 1–5000 µg/plate did 
not induce significant revertant colonies when compared 
with the negative control, and toxicity was observed to 
appear at concentration of 1000 and 5000 µg/plate of culture 
(Table 1).
Genotoxicity results of compound 1h measured by the CA 
assay are shown in Table 2. Knowing that 1h exhibited half 
maximal inhibitory concentration (IC50) value of around 
1 µM (1.5 µg/mL) when evaluated on various cancer 
cells, the CA assays were chosen to be carried out at three 
concentrations centered on this value. Thus, the experiments 
were conducted at concentrations of 1.5, 3 and 6 µg/mL.
No significant CA (percentage of aberrant cells) were 
observed in tested concentrations when compared to DMSO 
control culture. Results of the MI showed a slightly reduced 
MI for the highest dose even if not statistically significant 
suggesting cytotoxic/cytostatic effect at the highest dose (6 
µg/mL) (Table 2). The positive mutagen MMC showed very 
high frequencies of CA, which indicated that lymphocytes 
were cultured under proper conditions.
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Table 1. Results of mutagenicity assay induced by 1h and 1j in Salmonella strains TA98 and TA100 with and without S9 
activation.
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Table 1. Results of mutagenicity assay induced by 1h and 1j in Salmonella strains TA98 and 
TA100 with and without S9 activation. 
 
                                                                       Number of revertant / plate 
 
Dose (µg/plate)  
 
+ S9a  
 
 
- S9a  
 
  
+ S9a  
 
 
- S9a  
 
TA98 
Positive control 569.5 ± 34.6 505.8 ± 32.5    
Negative control 36.3 ± 7.9 26.8 ± 5.1   
 1h 1j 
1 35.8 ± 12.0 26.5 ± 6.2  35.8 ± 6.0 26.5 ± 4.2 
10 32.8 ± 11.1 26.3 ± 7.6 36.0 ± 7.3 27.0 ± 5.1 
100 34.5 ± 8.9 27.0  ± 6.7 *52.8 ± 7.5 *42.0 ± 5.5 
1000 35.5 ± 7.0 27.3 ± 5.0 *77.5 ± 3.9 *80.5 ± 9.6 
 5000 33.4 ± 9.4 25.0 ± 7.1  *92.0 ± 8.1 *98.9 ± 6.2 
    TA100 
Positive control 865.5 ± 62.6 1023.8 ± 195.9  
  
  
Negative control 190.5 ± 22.5 173.5 ±  23.3   
 1h 1j 
1 189.8 ±2 4.6 183.8 ± 25.7 194.5 ± 16.1 174.3 ± 30.6 
10 185.5 ± 23.3 178.5 ± 30.7 196.0 ± 18.4 176.5 ±  30.6 
100 188.0 ± 26.3 176.0 ± 22.0 193.5 ± 21.6 173.8 ±  33.4 
1000 *138.0 ± 14.3 *46.0 ± 12.9 *108.5 ± 11.8 *66.8 ±  18.1 
 5000 *53.8 ± 5.7 *12.3 ± 6.8  *62.2 ± 9.1 *26.9 ± 5.0 
 
 
*P˂0.05; negative control vs treatment. Dunnett Multiple Comparisons Test. DMSO (50 µL/plate) was used as negative 
control. 2-aminofluorene (2-AF) (5 µg/plate) was used as positive mutagen for both TA98 and TA100 strains with S9 
experiment; 4-Nitro-o-phenylenediamine (NPD) (20 µg/plate) was used as positive direct mutagen (positive control) in the 
absence of S9 mix for S. typhimurium TA98 strain. Sodium azide (SA) (1 µg/plate) was used as positive direct mutagen 
(positive control) in the absence of S9 mix for S. typhimurium TA100 
*P<0.05; negative control vs treatment. Dunnett Multiple Comparisons Test. DMSO (50 µL/plate) was used as negative control. 2-aminoflu-
orene (2-AF) (5 µg/plate) was used as positive mutagen for both TA98 and TA100 strains with S9 experiment; 4-Nitro-o-phenylenediamine 
(NPD) (20 µg/plate) was used as positive direct mutagen (positive control) in the absence of S9 mix for S. typhimurium TA98 strain. Sodium 
azide (SA) (1 µg/plate) was used as positive direct mutagen (positive control) in the absence of S9 mix for S. typhimurium TA100
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DISCUSSION
Benzothiazole is a heterocyclic ring having varied biological 
activities and still of great scientific interest (30). Piperazine 
is another important ring structure also investigated for 
the drug development intensively. Some studies reported 
that combination of benzothiazole and piperazine rings 
might lead to biologically active new structures with 
antimicrobial (31), antidepressant (32) and anticancer (33) 
effects. Recently, we have synthesized ten new benzothiazole-
piperazine derivatives as anti-tumor agents for the generation 
of a new class of antiproliferative compounds. Among them, 
1h and 1j were found to be the most active structures, and 
herein we aimed to investigate the safety of these molecules 
analyzing their possible mutagenicity and genotoxicity. 
Firstly, the possible mutagenic effects of these anticancer 
drug candidates were investigated by Ames mutagenicity 
assay carried out on Salmonella typhimurium strains. Ames 
test is a rapid bacterial reverse mutation assay specifically 
designed to detect a wide range of chemical substances 
capable of causing DNA damage leading to gene mutation 
that is used commonly as an initial screen to estimate the 
mutagenic potential of chemicals and drugs. The number of 
spontaneously induced revertant colonies per plate is relatively 
constant. However, when a mutagen sample is added to the 
plate, the number of revertant colonies per plate is increased, 
usually in a dose-related manner. A positive result indicates 
that the chemical or drug is mutagenic and hence may have 
a carcinogenic potential, because cancer is often linked to 
mutation (21). It should be considered important to clarify 
the structure-activity relationship of a novel molecule for 
mutagenicity. According to Hsu et al., all of the substituted 
structures derived from major mutagenic scaffolds were also 
mutagenic and the parent scaffolds with lack of mutagenicity 
may or not produce mutagenic derivatives depending on 
the attached substituent (34). Our results showed that 
(substituted – benzoyl) benzothiazol-piperazine was not 
mutagenic on both tested strains, whereas (substituted – 
2-furoyl) benzothiazol-piperazine was found to be strongly 
mutagenic to TA98 strain with or without S9 activation. It 
should be noted that anticancer agents that have been shown 
to be mutagenic in the Salmonella test yield a high risk of 
primary or secondary cancers following exposure to these 
drugs (35). The difference in the hydrophobicity of moieties 
is one of the causative factors for mutagenicity of chemical 
structures. Considering a possible effect of permeability of 
these investigated benzothiazol-piperazine derivatives across 
the cell membrane of the tested bacteria strain on their 
mutagenic activity, benzoyl residue was expected to across the 
membrane easily because of its more hydrophobic property 
compared to 2-furoyl moiety. Results of present study suggest 
that mutagenicity of these compounds cannot be attributed 
to a difference in the membrane permeability. On the basis of 
our observations, the cause of developing mutagenicity may 
be explained by the nature of each aromatic ring.
As seen in the Ames assay, 1h was found to be not mutagenic 
on TA98 and TA100 strains, so as recommended by the 
OECD guideline, (26) the in vitro CA assay was used to ensure 
the safety of 1h and to find out that this compound does not 
Table 2. Chromosomal aberrations induced by 1h in human lymphocytes in vitro.
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Table 2. Chromosomal aberrations induced b  1  in human lymphocytes in vitro. 
Treatment 
Metaphase 
cells scored 
Chromatid type 
abberation/cells 
Chromosome type 
abberations/cells 
Aberrant cells % 
(Mean ± S.D.) 
Mitotic indices 
(Mean±S.D.) 
Negative Control 200 0.070 0.080 7.50 ± 2.12 3.57 ± 0.74 
1h (1.5 µg/mL) 200 0.060 0.080 7.50 ±  1.41 3.03 ± 0.22 
1h ( 3.0 µg/mL) 200 0.010 0.090 7.00 ± 0.71 3.07 ± 0.18 
1h (6.0 µg/mL) 200 0.011 0.070 8.00 ± 1.41 2.18 ± 0.71 
Positive Control 200 0.250 0.200 19.50 ± 0.71* 3.22 ± 1.95 
 
Results at each dose were compared to those of negative control using Dunnett’s multiple comparison test. *p < 0.05: 
Positive control versus negative control using Dunnett’s multiple comparisons. Mitomycin C (MMC) 0.5 µg/mL was used as 
a positive control. DMSO (50µL) was used as a negative control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results at each dose were compared to those of negative control using Dunnett’s multiple comparison test. *p < 0.05: Positive control versus 
negative control using Dunnett’s multiple comparisons. Mitomycin C (MMC) 0.5 µg/mL was used as a positive control. DMSO (50µL) was 
used as a negative control.
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cause genotoxicity. CA analysis is utilized to assess potential 
genotoxic hazard of test substances. Mammalian cells are 
cultured in vitro, exposed to a test substance, harvested, 
and the frequency of asymmetrical structural chromosome 
aberrations is measured (36).
Two and four times higher concentrations than the average 
IC50 value previously determined on cancer cell lines were 
investigated for CA assay. Results revealed that 1h was 
not genotoxic even at the four times higher concentration 
than IC50 value in human lymphocytes culture. Many of 
the anticancer drugs are described to be genotoxic because 
they are designed to alter the DNA structure or its function. 
Since genotoxicity can result in the rise of secondary cancers, 
studying the generation of structures that do not exhibit any 
genotoxicity constitutes a trending research topic (37-39).
Taken together, the compound 1h is not mutagenic in 
bacterial strains TA98 and TA100 and also not genotoxic 
in human lymphocytes in vitro. Though some more studies 
on mutagenicity assays using another Salmonella tester 
strains together with in vivo studies are necessary before 
coming to a final decision, given the present mutagenicity 
and genotoxicity data, the use of (substituted–benzoyl) 
benzothiazole-piperazine analog seems to be suitable for 
the development of non-genotoxic anticancer agents. This 
structure can be optimized and designed without causing 
any genotoxic damage thus may be used safely in the future.
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Piperazin halkası taşıyan benzotiyazol türevlerinin 
toksikolojik değerlendirilmesi
ÖZET
Önceki çalışmalardan elde edilen 1h ve 1j adlı bileşikler 
potansiyel antikanser aktiviteye sahiptir. Antikanser 
ilaçların mutajenik ve genotoksik özelliklerinin bu ilaçların 
araştırılmasında temel konuyu oluşturması sebebiyle, çalışmada 
söz konusu moleküllerin mutajenite ve genotoksisite analizleri 
üzerinde durulmuştur. 1h ve 1j Moleküllerinin mutajeniteleri 
Salmonella TA98 ve TA100 suşları ile Ames testi uygulanarak 
belirlenmiştir. 1j Bileşiği TA98 bakteri suşu üzerinde mutajen 
bulunmuştur. Ancak, 1h bileşiğinin TA 100 ve TA98 suşları 
ile S9 varlığında ve yokluğunda mutajenik aktiviteye sahip 
olmadığı gösterilmiştir. 1h Bileşiğinin genotoksisitesi insan 
lenfositleri üzerinde yapılan kromozomal aberasyon testi 
ile değerlendirilmiş olup genotoksik bir risk oluşturmadığı 
saptanmıştır. Bütün sonuçlar değerlendirildiğinde, 1h’nin iki 
farklı Salmonella suşu üzerinde yapılan çalışmada mutajenik 
aktivitesi olmadığı ve kromozom aberasyon testinde genotoksik 
olmadığı saptanmıştır. Bu nedenle, sonuçları belirtilen 
molekülün mutajenik ve genotoksik etkileri olmadığı için yeni 
bir antikanser ilaç olarak umut verici olduğu görülmüştür. 
Güvenle kullanılabilecek antikanser aktivite sergileyen yeni bir 
molekülün varlığını göstermek için yukarıdaki analizlere ek 
olarak Ames testi tavsiye edilen diğer bakteri suşlarıyla ve in 
vivo deneylerle desteklenmelidir.
Anahtar Kelimeler: Benzotiyazol, piperazin, antikanser, 
mutajenite deneyi, genotoksisite, in vitro kromozomal 
aberasyon deneyi
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